Results 51 to 60 of about 14,058 (258)
British Journal of Clinical Pharmacology, EarlyView.Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Frontiers in PharmacologyBackground: The equivalence of generic drugs to their brand-name counterparts is a controversial issue. Current literature indicates disparities between the generic nebivolol (GN) and the brand nebivolol (BN).
Hongli Wang +6 more
semanticscholar +1 more source
Cardiovascular Drugs and Therapy, 2021 Bisoprolol and nebivolol are highly selective β 1 -adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and ...
W. Alhabeeb +2 more
semanticscholar +1 more source
Beta-blockers in COPD:time for reappraisal [PDF]
, 2016 The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in chronic obstructive pulmonary disease (COPD).
Devereux, Graham +4 more
core +3 more sources
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT We report a 54‐year‐old woman with stable angina who exhibited heterogeneous responses of tandem left anterior descending artery (LAD) plaques to intensive lipid‐lowering therapy. Coronary CT angiography performed at another hospital suggested diffuse disease, and she presented to our clinic for a second opinion.
Yong‐Lee Kim +9 more
wiley +1 more source
Pharmacology Research & PerspectivesAntihypertensive drug therapies have demonstrated their capacity to modulate the inflammatory processes associated with hypertension, leading to improvements in disease progression.
Lezama-Martinez Diego +5 more
semanticscholar +1 more source
Future Cardiology, 2021 According to the most recent international guidelines, β-blockers maintain a central role in the management of hypertension, being recommended at any treatment step when there is a specific indication, such as heart failure, angina, postacute myocardial ...
C. Ferri
semanticscholar +1 more source
The Effect of Nebivolol on Subarachnoid Hemorrhage-induced Vasospasm in the Rabbit
Bagcilar Medical Bulletin, 2019 Objective:This study aimed to investigate the vasorelaxation effect of nebivolol on vasospasm in the rabbit model of subarachnoid hemorrhage (SAH).Method:Single-hemorrhage model in the rabbit SAH was employed. SAH was induced in animals by cisterna manga
İlker Güleç, Ali Nail İzgi
doaj +1 more source
Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model
Frontiers in Physiology, 2017 Background: Hypertrophic cardiomyopathy (HCM) patients often present with diastolic dysfunction and a normal to supranormal systolic function. To counteract this hypercontractility, guideline therapies advocate treatment with beta-adrenoceptor and Ca2 ...
Sabrina Stücker +7 more
doaj +1 more source
Evaluation of Anticonvulsant Action of Nebivolol in Albino Mice
National Journal of Physiology, Pharmacy and Pharmacology, 2023 Background: Epilepsy is a disorder of brain function indicating periodic and unpredictable occurrence of seizures. Hypertension is the main cause of intracerebral hemorrhage which is a triggering factor for development of epilepsy. Nebivolol, a β-blocker
Balaji V +3 more
doaj +1 more source